Efficacy of Perioperative Chemotherapy for Resectable Pancreatic Adenocarcinoma | Zendy

Davendra Sohal | Zendy; Mai Duong | Zendy; Syed A. Ahmad | Zendy; Namita Gandhi | Zendy; Muhammad Shaalan Beg | Zendy; Andrea WangGillam | Zendy; James L. Wade | Zendy; E. Gabriela Chiorean | Zendy; Katherine A. Guthrie | Zendy; Andrew M. Lowy | Zendy; Philip A. Philip | Zendy; Howard S. Höchster | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Efficacy of Perioperative Chemotherapy for Resectable Pancreatic Adenocarcinoma

Author(s) -

Davendra Sohal,

Mai Duong,

Syed A. Ahmad,

Namita Gandhi,

Muhammad Shaalan Beg,

Andrea WangGillam,

James L. Wade,

E. Gabriela Chiorean,

Katherine A. Guthrie,

Andrew M. Lowy,

Philip A. Philip,

Howard S. Höchster

Publication year - 2021

Publication title -

jama oncology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 8.846

H-Index - 99

eISSN - 2374-2445

pISSN - 2374-2437

DOI - 10.1001/jamaoncol.2020.7328

Subject(s) - medicine , perioperative , gemcitabine , oxaliplatin , chemotherapy , performance status , folfirinox , irinotecan , chemotherapy regimen , pancreatic cancer , surgery , adenocarcinoma , clinical trial , oncology , cancer , colorectal cancer

Clinical outcomes after curative treatment of resectable pancreatic ductal adenocarcinoma (PDA) remain suboptimal. To assess the potential of early control of systemic disease with multiagent perioperative chemotherapy, we conducted a prospective trial.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research